Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PL
Polyrizon Ltd. Ordinary Shares
PLRZ
Mkt Cap
$23.1M
Volume
19.31K
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PL
PLRZ
PL
Polyrizon Ltd. Ordinary Shares
PLRZ
News
·
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
Mkt Cap
$24.3M
Volume
19.31K
Next Earnings
N/A
Chart
Financials
Earnings
News
About
Insider
Filings
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical-stage biotechnology company, announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the SEC. The company specializes in developing intranasal protective solutions using proprietary hydrogel technology delivered as nasal sprays to create a barrier against viruses and allergens.
GlobeNewswire Inc. · Mar 25, 2026
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray
Polyrizon successfully completed a pre-submission meeting with the FDA regarding its PL-14 Allergy Blocker nasal spray, discussing development plans, manufacturing, and clinical trial strategies for a potential product targeting the growing global allergen blocker market.
GlobeNewswire Inc. · Dec 8, 2025
US Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert
U.S. stock futures fell on Monday after a nine-day winning streak on the S&P 500 index. Investors will keep an eye on the Federal Reserve's decision on interest rates this week. Analysts say any de-escalation in trade tensions should be positive for the economy and financial markets.
Benzinga · May 5, 2025
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform
Polyrizon, a biotech company, has initiated preclinical studies for intranasal Naloxone, a treatment for opioid overdose, using its Trap and Target (T&T) platform. The studies aim to assess key parameters like drug loading, release kinetics, and nasal deposition, paving the way for further safety and efficacy testing.
GlobeNewswire Inc. · Mar 10, 2025
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform
Polyrizon, a biotech company, announced the filing of a divisional patent application for its Trap & Target (T&T) intranasal drug delivery platform. The T&T platform aims to enhance the effectiveness of medications by increasing their residence time and bioavailability.
GlobeNewswire Inc. · Jan 30, 2025
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
Polyrizon, a biotech company, has signed a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S to supply Clinical Trial Material for its PL-14 allergy blocker in preparation for a planned 2025 clinical trial.
GlobeNewswire Inc. · Dec 2, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
PL
PLRZ
Polyrizon Ltd. Ordinary Shares
Buy
Sell
Market
Limit
Soon
PLRZ
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any PLRZ yet.
Related Tickers
Earnings